Savara General and Administrative Expenses 2011-2025 | SVRA

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Savara

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
15.7 M	10.9 M	12.4 M	14.3 M	13.1 M	10.7 M	11.1 M	9.34 M	11 M	9.49 M	8.52 M	7.52 M	7.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
15.7 M	7.52 M	10.9 M

Quarterly General and Administrative Expenses Savara

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9.63 M	10.7 M	9.25 M	-	6.01 M	5.54 M	5.64 M	-	4.15 M	3.3 M	3.37 M	-	2.38 M	2.96 M	2.35 M	-	3.4 M	3.15 M	2.78 M	-	5.38 M	3.12 M	2.98 M	-	2.81 M	4.21 M	2.76 M	-	3.15 M	2.49 M	1.77 M	-	1.49 M	5.09 M	1.74 M	-	1 M	608 K	2.84 M	-	2.46 M	2.41 M	3.58 M	-	2.46 M	2.37 M	2.27 M	-	2.16 M	2.1 M	2.11 M	-	1.82 M	1.87 M	2.05 M	-	1.98 M	1.82 M	1.57 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
10.7 M	608 K	3.31 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	22.5 M	$ 4.85	3.03 %	$ 805 M	Canada
Aclaris Therapeutics ACRS	22.2 M	$ 3.24	-0.46 %	$ 250 M	USA
AlloVir ALVR	42.9 M	-	4.14 %	$ 49.1 M	USA
Aptevo Therapeutics APVO	10.2 M	$ 1.06	-6.19 %	$ 293 K	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Ascendis Pharma A/S ASND	160 M	$ 216.6	-1.74 %	$ 5 B	Danmark
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.14	-4.56 %	$ 7.55 B	Australia
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
BioVie BIVI	8.57 M	$ 1.37	-5.21 %	$ 2.02 M	USA
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	73.5 M	-	-15.15 %	$ 60.3 M	Britain
BioNTech SE BNTX	286 M	$ 93.82	-1.04 %	$ 27.2 B	Germany
Aeglea BioTherapeutics AGLE	45.8 M	-	-	$ 1.01 B	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
Alpine Immune Sciences ALPN	18 M	-	-	$ 2.17 B	USA
Ampio Pharmaceuticals AMPE	7.08 M	-	-11.43 %	$ 502 K	USA
Amphastar Pharmaceuticals AMPH	56.7 M	$ 26.28	3.99 %	$ 1.27 B	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Anika Therapeutics ANIK	95.8 M	$ 9.56	-	$ 140 M	USA
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 0.27	-7.19 %	$ 588 M	Israel
Arena Pharmaceuticals ARNA	126 M	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	20.1 M	-	3.77 %	$ 22.4 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Catalyst Biosciences CBIO	14.7 M	$ 13.75	-2.41 %	$ 905 M	USA
Avenue Therapeutics ATXI	4.64 M	-	-52.27 %	$ 4.45 M	USA
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Axon Enterprise AXON	741 M	$ 545.68	-3.3 %	$ 41.3 B	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
Aytu BioScience AYTU	17.4 M	$ 2.37	3.04 %	$ 14.9 M	USA
AstraZeneca PLC AZN	15.2 B	$ 91.17	1.49 %	$ 96.9 B	Britain
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Burford Capital Limited BUR	99.3 M	$ 8.9	-1.22 %	$ 1.45 B	Britain
BeiGene, Ltd. BGNE	1.83 B	-	0.49 %	$ 251 B	Cayman-islands
Biohaven Pharmaceutical Holding Company Ltd. BHVN	714 M	$ 11.36	-1.52 %	$ 735 M	USA
Biogen BIIB	2.4 B	$ 173.96	-0.08 %	$ 25.3 B	USA
Abeona Therapeutics ABEO	19 M	$ 5.09	-5.13 %	$ 109 M	USA
Celldex Therapeutics CLDX	38.5 M	$ 27.29	-0.8 %	$ 1.76 M	USA
ADiTx Therapeutics ADTX	16.3 M	$ 1.65	-26.34 %	$ 21.7 K	USA
Cellectar Biosciences CLRB	11.7 M	$ 3.41	-5.8 %	$ 41.7 M	USA
Bellicum Pharmaceuticals BLCM	5.72 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	95.1 M	-	-7.31 %	$ 87 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Завод ДИОД DIOD	19.7 M	-	-	-	Russia
Фармсинтез LIFE	24.1 M	-	-	-	Russia